BTIG Maintains Buy on GE HealthCare Techs, Raises Price Target to $91
BTIG analyst Ryan Zimmerman maintains GE HealthCare Techs (NASDAQ:GEHC) with a Buy and raises the price target from $83 to $91.
Last updated: 2026-11-19 02:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GE HealthCare Technologies Inc. (GEHC) operates in the X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $83.69, with a market capitalization of $37.51B and a P/E ratio of 17.18. Over the past 52 weeks, its price has ranged from $58.75 to $89.77. This page covers its latest market performance, valuation, price trends and company information.
$37.51B | |
$81.31 | |
$83.99 | |
$80.99 | |
$81.84 | |
2.79M | |
3.68M | |
17.18 | |
$89.77 | |
$58.75 | |
0.17% | |
2026-09-30 |
GE HealthCare Technologies Inc. (GEHC) last closed at $83.69 as of 2026-11-19 00:58:00, up 2.22% ($1.82) from the previous close of $81.84.
During the latest regular trading session, GEHC traded between $80.99 and $83.99, with a volume of 2.79M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, GE HealthCare Technologies Inc. (GEHC) moved from $84.03 to $83.69, representing a decline of 0.41% ($0.34).
The stock traded between $80.99 and $84.66 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 3.17 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.4%
GEHC is currently trading at $83.69, placing it 80.4% of the way from its 52-week low of $58.75 to its 52-week high of $89.77. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
| Industry | X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS |
| Employees | 54,000 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for GE HealthCare Technologies Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Oct 23, 2026 |
| Payment Date | Nov 13, 2026 |
| Dividend Per Share | $0.04 |
Latest news related to GE HealthCare Technologies Inc. and GEHC stock.
BTIG analyst Ryan Zimmerman maintains GE HealthCare Techs (NASDAQ:GEHC) with a Buy and raises the price target from $83 to $91.
As the latest evolution of the portfolio, Critical Care Suite 3.0 extends support to pediatric patients for the first time with feeding tube assessment capabilities.Mobile X-ray plays an important role in emergency and
Following recent global regulatory clearances, leading academic hospitals and research institutions across North America, Europe and Asia are beginning structured evaluations of Photonova Spectra to further define its
GE HealthCare raised its full-year 2026 organic revenue guidance to 4% and reported 6.2% organic revenue growth in Q3 2026. The company's equipment backlog grew 12% year-over-year to $23.7 billion. Key strengths include recurring revenue from its Pharmaceutical Diagnostics division, operational improvements through the Heartbeat operating system, and multiyear supply agreements for memory chips that provide manufacturing resilience amid industry shortages.
Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.
Eligible investors can buy real shares of GE HealthCare Technologies Inc. (GEHC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GEHC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GEHC shares and USD.
GEHC Shares to USD
1.00 GEHC shares = 83.687 USD
Calculations are estimates based on the latest available price and are for reference only.